Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg ) is a monoclonal antibody used to treat acute myelogenous leukemia .

It is a monoclonal antibody to CD33 linked to a cytotoxic agent, calicheamicin . more

Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg ) is a monoclonal antibody used to treat acute myelogenous leukemia .

It is a monoclonal antibody to CD33 linked to a cytotoxic agent, calicheamicin . CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, the intensity diminishing with maturation of stem cells . When given to patients in first relapse, 15% of patients achieve a complete remission. In the United States, it was approved by the FDA for use in patients over the age of 60 with relapsed acute myelogenous leukemia (AML) who are not considered candidates for standard chemotherapy. [ 1 ] less